144 results on '"Evers, B. Mark"'
Search Results
2. Figure S1 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
3. Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells
4. Figure S2 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
5. Supplementary Data from Potent Synergistic Effect on C-Myc–Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor
6. Figure S4 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
7. Figure S5 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
8. Figure S1 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
9. Figure S3 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
10. Figure S2 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
11. Data from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
12. Data from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
13. Figure S5 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
14. Supplementary Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells
15. Figure S3 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
16. Figure S6 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
17. Figure S6 from De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
18. Supplementary Data from Potent Synergistic Effect on C-Myc–Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor
19. Supplementary Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells
20. Supplementary Figure 3 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
21. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
22. Supplementary Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer
23. Supplementary Movie S6 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
24. Supplementary Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer
25. Supplementary Movie S4 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
26. Supplementary Figure 5 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
27. Supplementary Movie S2 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
28. Supplementary Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer
29. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
30. Supplementary Movie S6 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
31. Supplementary Movie S4 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
32. Supplementary Figure 5 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
33. Supplementary Movie S8 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
34. Supplementary Figure 4 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
35. Supplementary Movie S1 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
36. Supplementary Figure 2 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
37. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
38. Supplementary Data from Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
39. Supplementary Movie S2 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
40. Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer
41. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
42. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
43. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
44. Supplementary Figure 1 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
45. Supplementary Figure 1 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
46. Supplementary Movie S7 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
47. Supplementary Data from Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
48. Supplementary Figure 4 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
49. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
50. Supplementary Movie S3 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.